NYSE:CTLT (USA)
Business Description
Catalent Inc
NAICS : 325412
SIC : 2834
14 Schoolhouse Road, Somerset, NJ, USA, 08873
Compare
Compare
Traded in other countries / regions
0C8.Germany
•
CTLT.Mexico
•
CTLT.USA
Description
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.21 | |||||
| Equity-to-Asset | 0.45 | |||||
| Debt-to-Equity | 0.91 | |||||
| Debt-to-EBITDA | 3.86 | |||||
| Interest Coverage | 6.2 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.02 | |||||
| Beneish M-Score | -2.25 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.3 | |||||
| 3-Year EBITDA Growth Rate | 24.4 | |||||
| 3-Year EPS without NRI Growth Rate | 70.3 | |||||
| 3-Year Book Growth Rate | 41.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | 11.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 13.99 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.66 | |||||
| 9-Day RSI | 45.88 | |||||
| 14-Day RSI | 48.96 | |||||
| 6-1 Month Momentum % | 5.31 | |||||
| 12-1 Month Momentum % | -14.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.89 | |||||
| Quick Ratio | 2.23 | |||||
| Cash Ratio | 0.84 | |||||
| Days Inventory | 75.23 | |||||
| Days Sales Outstanding | 69.55 | |||||
| Days Payable | 44.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.5 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.83 | |||||
| Operating Margin % | 16.2 | |||||
| Net Margin % | 10.91 | |||||
| ROE % | 11.15 | |||||
| ROA % | 5.28 | |||||
| ROIC % | 7.99 | |||||
| ROC (Joel Greenblatt) % | 22.69 | |||||
| ROCE % | 8.57 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 38.97 | |||||
| Forward PE Ratio | 27.47 | |||||
| PE Ratio without NRI | 38.97 | |||||
| Shiller PE Ratio | 93.93 | |||||
| Price-to-Owner-Earnings | 159.33 | |||||
| PEG Ratio | 2.51 | |||||
| PS Ratio | 4.01 | |||||
| PB Ratio | 4.15 | |||||
| Price-to-Tangible-Book | 36.41 | |||||
| Price-to-Operating-Cash-Flow | 37.4 | |||||
| EV-to-EBIT | 30.62 | |||||
| EV-to-Forward-EBIT | 22.81 | |||||
| EV-to-EBITDA | 20.75 | |||||
| EV-to-Forward-EBITDA | 16.56 | |||||
| EV-to-Revenue | 4.8 | |||||
| EV-to-Forward-Revenue | 4.26 | |||||
| EV-to-FCF | -206.79 | |||||
| Price-to-Projected-FCF | 4.94 | |||||
| Price-to-DCF (Earnings Based) | 2.84 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.95 | |||||
| Price-to-Graham-Number | 7.89 | |||||
| Earnings Yield (Greenblatt) % | 3.26 | |||||
| Forward Rate of Return (Yacktman) % | 19.85 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:CTLT
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4,703 | ||
| EPS (TTM) ($) | 2.76 | ||
| Beta | 1.15 | ||
| Volatility % | 35.37 | ||
| 14-Day RSI | 48.96 | ||
| 14-Day ATR ($) | 3.364683 | ||
| 20-Day SMA ($) | 109.947 | ||
| 12-1 Month Momentum % | -14.5 | ||
| 52-Week Range ($) | 86.34 - 142.64 | ||
| Shares Outstanding (Mil) | 179.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Catalent Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||